All studies
Cardiology · EHR · US

Wang 2026

Heart failure with reduced ejection fraction

DAG reportedITTSuperiorityAcademia, Government2/5 disclosures
Comparisons
1
In the analysis
0
1 withheld
Target trials
1
Emulations reported
1
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
All-cause mortality
vs PARADIGM-HF device subgroup·HR·Efficacy
0.810.61–1.06
0.930.61–1.42
not pooledClose alignment

Design and methods

Estimand
ITT
Design hypothesis
Superiority
Matching / weighting
IPTW using logistic regression and gradient boosting
Analysis method
Weighted Cox proportional hazards model
Missing data
Not reported
DAG
Yes
QBA
No

Data and sample

Data type
EHR
Data sources
1
Geography
US
Eligible sample
2447
Treated
583
Control
1864
Emulations
1
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry, Government
COI institutions
Patents and industry relationships listed in the report
Funding
Declared: Public
Funders
National Institutes of Health and US Department of Veterans Affairs

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Wang_PARADIGMHF
DOI
10.1007/s10654-025-01341-7
Affiliations
US Department of Veterans Affairs and academic collaborators
Sector
Academia, Government
Target trials (study level)
PARADIGM-HF device subgroup
Registration
NCT01035255